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Abstract
Background: Artemisinin-based combination therapy (ACT) is the first-line malaria treatment throughout most of
the malaria-endemic world. Data on ACT availability, price and market share are needed to provide a firm evidence
base from which to assess the current situation concerning quality-assured ACT supply. This paper presents supply
side data from ACTwatch outlet surveys in Benin, the Democratic Republic of Congo (DRC), Madagascar, Nigeria,
Uganda and Zambia.
Methods: Between March 2009 and June 2010, nationally representative surveys of outlets providing anti-malarials
to consumers were conducted. A census of all outlets with the potential to provide anti-malarials was conducted
in clusters sampled randomly.
Results: 28,263 outlets were censused, 51,158 anti-malarials were audited, and 9,118 providers interviewed. The
proportion of public health facilities with at least one first-line quality-assured ACT in stock ranged between 43%
and 85%. Among private sector outlets stocking at least one anti-malarial, non-artemisinin therapies, such as
chloroquine and sulphadoxine-pyrimethamine, were widely available (> 95% of outlets) as compared to first-line
quality-assured ACT (< 25%). In the public/not-for-profit sector, first-line quality-assured ACT was available for free
in all countries except Benin and the DRC (US$1.29 [Inter Quartile Range (IQR): $1.29-$1.29] and $0.52[IQR: $0.00-
$1.29] per adult equivalent dose respectively). In the private sector, first-line quality-assured ACT was 5-24 times
more expensive than non-artemisinin therapies. The exception was Madagascar where, due to national social
marketing of subsidized ACT, the price of first-line quality-assured ACT ($0.14 [IQR: $0.10, $0.57]) was significantly
lower than the most popular treatment (chloroquine, $0.36 [IQR: $0.36, $0.36]). Quality-assured ACT accounted for
less than 25% of total anti-malarial volumes; private-sector quality-assured ACT volumes represented less than 6%
of the total market share. Most anti-malarials were distributed through the private sector, but often comprised non-
artemisinin therapies, and in the DRC and Nigeria, oral artemisinin monotherapies. Provider knowledge of the first-
line treatment was significantly lower in the private sector than in the public/not-for-profit sector.
Conclusions: These standardized, nationally representative results demonstrate the typically low availability, low
market share and high prices of ACT, in the private sector where most anti-malarials are accessed, with some
exceptions. The results confirm that there is substantial room to improve availability and affordability of ACT
* Correspondence: koconnell@psi.org
1Population Services International, Malaria & Child Survival Department, P.O.
Box 43640, Nairobi, Kenya
Full list of author information is available at the end of the article
O’Connell et al. Malaria Journal 2011, 10:326
http://www.malariajournal.com/content/10/1/326
© 2011 O’Connell et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
treatment in the surveyed countries. The data will also be useful for monitoring the impact of interventions such
as the Affordable Medicines Facility for malaria.
Background
In 2000, African Heads of State agreed in Abuja that by
2010 60% of people with malaria would be able to
access “affordable and appropriate treatment within 24
hours of the onset of symptoms“ [1]. This target was
increased to 80% in 2005 [2]. Artemisinin-based Combi-
nation Therapy (ACT) is the first-line malaria treatment
throughout most of the malaria-endemic world.
Although public sector procurement of ACT has
increased sharply in recent years, it was estimated that
in 2009 less than 15% of children under five years of age
received ACT when they had fever in 11 of 13 African
countries, and only 32% received anti-malarials of any
kind [3]. Furthermore, the availability and use of oral
artemisinin monotherapy [4,5] is worrying given the risk
of development of artemisinin resistance [6] and WHO’s
recommendation to countries to ban the importation
and manufacturing of these drugs.
A variety of country-specific studies have raised
important concerns about ACT supply that may explain
these low levels of ACT use. Studies have generally
found low availability of ACT and higher availability of
monotherapies in both the public and private sector
[7-9]. While ACT is typically free-of-charge or subsi-
dized in the public and not-for-profit sector, in the pri-
vate sector ACT is between ten and twenty times more
expensive than non-artemisnin therapies, such as chlor-
oquine and sulphadoxine-pyrimethamine (SP) [8,10-12].
Provider knowledge that ACT is the first-line treatment
for malaria is also low, particularly in the private sector
[13-16].
Research addressing questions on the anti-malarial
market is typically limited in geographical scope and uti-
lizes a variety of different methods to ascertain price and
availability. Data are typically collected in a few purpo-
sively selected geographical areas within one country,
and at times include only certain outlet types or sectors.
Studies are not typically designed with sufficient power
to detect differences between sectors. With a few excep-
tions [14,17-20], there is little evidence on the market
share of anti-malarial medicines sold through the private
retail sector, where most malaria treatment is sought.
The available data, therefore, fail to provide a firm evi-
dence base from which to assess the current situation
concerning ACT supply across countries, or to help
evaluate the impact of important initiatives to improve
this, such as the Affordable Medicines Facility for
Malaria (AMFm), which provides heavily subsidized,
quality assured, ACT to pilot countries [21].
Standardized information on availability, price and mar-
ket share of ACT and other anti-malarials in the public/
not-for-profit and private sectors will inform such inter-
ventions and help gauge their relative success, guiding
policy makers and programmers at the national and
international levels.
To help address some of these gaps, Population Ser-
vices International (PSI) in partnership with the London
School of Hygiene and Tropical Medicine (LSHTM)
launched a five-year multi-country research project in
2008 called ACTwatch to monitor anti-malarial supply
and demand in seven malaria endemic countries in
Africa and Asia. This involves multiple surveys of
households and anti-malarial outlets, and a systematic
analysis of the anti-malarial supply chain in Benin, Cam-
bodia, the Democratic Republic of Congo (DRC), Mada-
gascar, Nigeria, Uganda and Zambia [22].
This paper presents the results from ACTwatch outlet
surveys carried out between March 2009 and June 2010
in the six sub-Saharan countries. An ACT was the first-
line anti-malarial in all these countries at the time of
the study, with artemether-lumefantrine and/or artesu-
nate-amodiaquine the recommended combination. All
countries recommended quinine for treatment of severe
malaria, and SP for intermittent preventive treatment in
pregnancy.
Methods
Design & sampling
A nationally representative sample of outlets providing
anti-malarials to consumers was selected. Each country
was first stratified using information on country size,
malaria endemicity, geopolitical areas, or urbanization.
Benin was designated as a single stratum; Madagascar,
Uganda, and Zambia were divided into two strata; the
DRC into four and Nigeria into six [22]. Stratification
was agreed in consultation with national authorities
including the national malaria control programme and
the national drug regulatory authority.
Following stratification, a one-stage probability-pro-
portional-to-size (PPS) cluster design was used to select
clusters within each stratum, with cluster population
serving as the measure of size. The primary sampling
unit, or cluster, selected was an administrative unit with
10,000 to 15,000 inhabitants. The proportion of outlets
with any ACT in stock was used as a key indicator for
sample size calculation, conservatively estimated at 40%
for each country. A minimum of 290 outlets with anti-
malarials in stock was needed to detect a 20% increase
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in this indicator, at 80% power, setting the level of sig-
nificance at 5% and adjusting for an estimated design
effect of 3. It was estimated that the selection of 19 clus-
ters per stratum would provide at least this number of
outlets stocking anti-malarials.
Within each selected cluster all outlet types with the
potential to provide anti-malarials to consumers were
sampled, with the identification of these outlet types
based on available literature and local knowledge. The
main types of outlets sampled included public and not-
for profit health facilities, private health facilities, phar-
macies, drug stores and grocery stores/kiosks. In addi-
tion, a range of other outlet types were considered
relevant in specific countries, for example, market stalls
in Benin, gargotes in Madagascar, itinerant vendors in
Nigeria and Benin, and community health workers in
Nigeria, Uganda and Madagascar.
As public health facilities and pharmacies are impor-
tant providers of anti-malarials but are relatively uncom-
mon, over-sampling was conducted for these outlet
types. This booster sample was obtained by including
public health facilities and pharmacies in the larger
administrative area from which a given cluster was
selected. For example, if the cluster was defined as the
sub-district, the booster sample covered all public health
facilities and pharmacies in the whole district within
which the sub-district was located.
Training and fieldwork
The outlet surveys were conducted during the months
of peak malaria transmission in each country. The sur-
vey data were collected by teams of between 21 and 76
enumerators with at least 12 years of education who
were fluent in the local language. Interviewer training
was provided over six days, focusing on outlet identifica-
tion, informed consent procedures, and the procedures
for completing the questionnaire.
Field workers were provided with a list of selected
clusters and maps that illustrated their administrative
boundaries, in addition to lists of public health facilities
and pharmacies obtained from relevant authorities.
Snowball sampling was also used by field workers to
identify facilities that were not on official lists. In each
selected cluster, fieldworkers conducted a census of all
outlets that had the potential to provide anti-malarials.
For each outlet that was identified during the census,
the outlet type and location were noted, along with its
longitude and latitude coordinates (obtained via hand-
held global positioning units). A fieldworker then
approached the outlet’s main seller or provider and
invited him or her to participate in the study. Providers
who agreed to participate were asked two screening
questions to determine whether (a) the outlet had
stocked anti-malarials within the previous three months,
and (b) anti-malarials were available on the day of the
survey. All providers answering “yes” to at least one of
these questions were deemed eligible for inclusion in
the survey and the questionnaire was administered to
these outlets. An interview with the staff member who
was most likely to sell or prescribe medications was
conducted.
The interview was carried out in the appropriate local
language. Questionnaires were pre-tested and validated
in each country before data collection.
The questionnaire consisted of two parts. A drug audit
collected information on all anti-malarials found at the
time of the interview, including information on brand
and generic names, dose, manufacturer, amount sold in
the last seven days, and retail price. The provider ques-
tionnaire collected information on provider demo-
graphics, anti-malarial treatment knowledge, anti-
malarial storage conditions, stock-outs, and licensing.
Data collection lasted from one to five months in each
country and took place between March 2009 and June
2010 (Benin, April 28th - May 13th 2009; the DRC,
August 10th - October 27th 2009; Madagascar, April 27th
- June 21st 2010; Nigeria August 4th - September 16th
2009; Uganda, March 16th - April 7th 2009; Zambia,
April 14th - July 3rd 2009).
During data collection, approximately 80% of all ques-
tionnaires were reviewed by the team supervisor and 15-
20% of all outlets were revisited by a supervisor or/and
quality controller for quality control checks.
Data analysis
Double data entry was conducted using Microsoft
Access (Microsoft Corporation, Redmond, Washington,
USA) with built-in range and consistency checks.
Entered data were triangulated with questionnaires, field
supervision notes and daily activity logs filled by each
interviewer in the field. Data were analysed using Stata
11.0 (StataCorp College Station, TX).
Stata survey settings were used to account for the
stratified and clustered sampling strategy. Results were
adjusted by sampling weights. Sampling weights were
based on the inverse of the probability of selection to
allow for the differences in strata and cluster sizes and
the oversampling of public health facilities and pharma-
cies. Distribution of the outlets was assumed to be pro-
portional to population size. Data analysis included
descriptive summaries; between-group proportions were
compared using chi-square analysis and median prices
compared using the Wilcoxon rank sum test.
For the presentation of results, outlets were grouped
into two categories: 1) the public and not-for-profit sec-
tor, and 2) the private sector. The former included pub-
lic health facilities, facilities supported by NGOs,
mission hospitals and/or community health workers.
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The private sector included all for-profit outlets. For the
purpose of analysis, anti-malarials were classified into
ACT, non-artemisinin therapies (such as chloroquine
and SP) and artemisinin monotherapies. ACT was clas-
sified as two mutually exclusive categories: quality-
assured (appearing on the WHO list of approved formu-
lations of ACT or the UNICEF procurement records)
and non-quality assured. Quality-assured ACT was
further divided into 1) quality-assured first-line ACT
and 2) quality-assured non first-line ACT (see Table 1).
Artemisinin monotherapies were further divided into
oral and non-oral artemisinin monotherapies. Data were
not collected on drugs intended solely for malaria che-
moprophylaxis as the focus was on drugs for treatment.
The antibiotic cotrimoxazole was also excluded as,
although it has anti-malarial properties, it is very rarely
used as a malaria treatment.
Availability
Availability was calculated using two methods. For each
country, availability of anti-malarials was measured as
the proportion of outlets with at least one anti-malarial
in stock, among all censused outlets. Within each coun-
try, the availability of specific anti-malarial categories,
restricted to those outlets that had anti-malarials in
stock, was also calculated. Thus, for example, the avail-
ability of ACT was measured as the proportion of out-
lets stocking ACT, among all outlets with at least one
anti-malarial in stock.
In a supplementary analysis, the availability in public
health facilities was also measured as the proportion of
facilities with different categories of anti-malarials in
stock, among all censused public health facilities. This
operationalized the expectation that public health facil-
ities should stock anti-malarials.
Volumes and price
The volume sold/distributed and retail price of the anti-
malarials recorded in the drug audit were standardized
using the adult equivalent treatment dose (AETD) to
allow meaningful comparisons between anti-malarials
with different treatment courses. For the five countries
that conducted surveys in 2009, prices were converted
to US dollars using their average annual exchange rate
[23]. For Madagascar (where data were collected in
2010), local currency prices were adjusted to 2009 prices
using the Madagascar consumer price index [24], and
then converted to US dollars using the 2009 average
exchange rate.
Prices per AETD are presented for the three anti-
malarial categories believed to be most pertinent to pol-
icy level decisions; first-line quality-assured ACT, the
most popular anti-malarial based on volume (defined by
generic name), and oral artemisinin monotherapy.
Price measures include tablet anti-malarials only as
this is the most common formulation. The price of non-
tablet formulations, such as powders for reconstitution,
suspensions, suppositories and syrups, was excluded.
The price distributions for these non-tablet formulations
tend to be different from those for tablets, with much
higher medians, implying that it could be misleading to
use one measure of central tendency for all formula-
tions. However, measures of volume include all dosage
forms to provide a complete assessment of anti-malarial
market shares.
Ethical approval
The study was approved by the local ethical review
boards: Benin Ministry of Health, Authorization for
Data Collection Number 3989/MS/DC/SGM/DRS/SCI/
SA, 14th July 2008; Cambodia, Ministry of Health,
Table 1 Description of Quality-Assured ACT classifications
First-line quality-assured ACTs: Non first-line quality-assured ACTs:
Definitions Government recommended first-line treatments (regardless of
strength) for uncomplicated malaria that appear on the WHO list
of approved ACTs or the UNICEF procurement records.
Brands on these lists and audited in each country were:
ACTs that are not the government’s recommended first-line
treatment for uncomplicated malaria, but which appear on the
WHO list of approved ACTs or the UNICEF procurement records.
Brands on these lists and audited in each country were:
Benin Artefan 20/120; Coartem; Lumartem 20/120; Lumet 20/120 Coarsucam; Winthrop
DRC Arsuamoon; Artesunate & Amodiaquine from Ipca; Artesunate &
Amodiaquine from Cipla; Falcimon Kit; Serenadose; Coarsucam;
Winthrop
Artefan 20/120; Coartem 20/120; Lumartem 20/120
Madagascar Arsuamoon; Artesunate & Amodiaquine from Ipca; Actipal 50/153;
Winthrop; Coarsucam; Falcimon kit; Larimal
Artefan 20/120; Coartem 20/120;
Coartem D 20/120;
Lumartem 20/120
Nigeria Coartem 20/120; Coartem D 20/120; Lumerax 20/120 *Arsuamoon;
*Coarsucam; *Larimal
Artecospe
Uganda Coartem; Artefan 20/120; Lumartem 20/120 Larimal, Falcimon kit
Zambia Artefan 20/120; Coartem 20/120; Lumartem 20/120; Lumerax;
Lumet 20/120
Arsuamoon; Artecospe
*Alternate first-line treatment in Nigeria
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National Ethics Review Committee, Reference Number
109 NECNR, 7th November 2008; Democratic Republic
of Congo, Ministerie de L’Enarignement Superior at
Universitaire, School of Public Health, Reference Num-
ber ESP/CF/020/2008, 11th June 2008; Madagascar, Min-
istry of Health du Planning Familial et de la Protection
Sociale, Reference Number 206SANPFPS, 16th June
2008; Nigeria; Federal Department of Ministry of Health,
Department of Public Health, Reference Number MH/
1158/5/137, 20th October 2008; Uganda, Makerere Uni-
versity, Faculty of Medicine, Reference Number 2008-
057, 1st September 2008; and Zambia, University of
Zambia, Biomedical Ethical Research Committee, Refer-
ence Number 014-08-08, 2nd October 2008.
Results
A total of 28,263 outlets across six countries were
approached to participate in the surveys. In total, 348
outlets were closed down permanently, 665 outlets were
not open, 299 eligible providers were not available for
interview, 395 providers refused to participate and 301
outlets were excluded for other reasons. As a result,
26,255 outlets were screened for stocking anti-malarials.
Of these, 9,118 outlets met the screening criteria and
were administered the questionnaire (8,383 outlets were
found to have at least one anti-malarial in stock and
735 outlets had no anti-malarials in stock at the time
but reported having stocked anti-malarials in the past
three months).
Among outlets stocking anti-malarials on the day of
survey, 51,158 individual anti-malarial products were
audited (66% tablets). The proportion of tablet forma-
tions in the audit varied by country (Benin, 73%, n=5,
232; the DRC, 58%, n=11, 939; Madagascar, 87%,
n=5,579; Nigeria, n=61%; n=20,841; Uganda, 63%,
n=5,784; and Zambia, 82%, n=1,783).
Availability
Table 2 shows the availability of anti-malarials as the
proportion of outlets with at least one anti-malarial in
stock, among all censused outlets. The proportion of
outlets with any anti-malarials in stock at the time of
the interview varied by outlet type. Overall, stocking
rates in the public/not-for-profit sector were generally
high (~90%) with the exception of Madagascar (40%)
and Uganda (70%). Both these countries had large num-
bers of CHWs included in the census, with less than
half of these providers having anti-malarials available
(27% and 40% respectively). In public health facilities,
stocking rates were greater than 90% across all
countries.
In the private sector, stocking of anti-malarials was
lower and varied by outlet type and country, ranging
from 6% in Zambia to 36% in Benin. Private health
facilities, pharmacies and drug stores were more likely
to stock anti-malarials than grocery stores and other
outlets, where stocking rates were generally less than
5%. Exceptions were grocery stores in Benin and Mada-
gascar and market stalls in Benin, with around one in
three of these outlets stocking anti-malarials.
Figure 1 shows the relative distribution of all outlets
that had at least one anti-malarial in stock, by country.
Results show the diversity of distribution of outlet types
stocking anti-malarials. For example, public health facil-
ities varied from 4% of all outlets stocking anti-malarials
in Nigeria to 31% in Zambia. In Madagascar, grocery
stores constituted 73% of all outlets stocking anti-malar-
ials, as compared to 2% in Uganda. Drug stores were
the most common type of outlet stocking anti-malarials
in Nigeria, Uganda and the DRC; groceries and stalls
were most common in Madagascar and Benin respec-
tively; and public health facilities were the most com-
mon outlets stocking anti-malarials in Zambia.
Among outlets stocking at least one anti-malarial
(Table 3), non-artemisinin therapies were generally the
most commonly stocked category of anti-malarial in both
the public/not-for-profit sector and private sector. A sig-
nificant exception to this was found in Madagascar’s pub-
lic/not-for-profit sector, which was more likely to stock
first-line quality-assured ACT (92%) than non-artemisi-
nin therapies (36%). In the private sector, stocking rates
of first-line quality-assured ACT were less than 25%
across all countries, and for most countries significantly
lower than the public/not-for-profit sector (p < .05)
(Table 3). Stocking rates of oral artemisinin monothera-
pies were generally low, though exceptions included pri-
vate sector outlets in the DRC (41%) and Nigeria (45%).
Availability of different categories of anti-malarials in
public health facilities was also calculated among all
censused public health facilities (see Additional File 1
Table 1). Among all public health facilities (excluding
community health workers), stockage rates of first-line
quality-assured ACT at the time of survey were as fol-
lows: Benin, 81%; the DRC, 82%; Madagascar, 80%;
Nigeria 43%; Uganda, 72% and Zambia, 85%. The stock-
ing rate of SP among all outlets in the public sector,
used in intermittent preventive treatment of pregnant
women (IPTp), also varied (Benin, 50%; the DRC, 70%;
Madagascar, 46%; Nigeria 63%; Uganda, 62% and Zam-
bia, 59%). Quinine injection, the government-recom-
mended treatment for severe malaria for persons who
cannot take oral medication, ranged in public sector
availability as well: Benin, 61%; the DRC, 66%; Madagas-
car, 43%; Nigeria 16%; Uganda, 73% and Zambia, 53%.
Price
First-line quality-assured ACT was free at public sector
outlets in four of the six countries. In Benin and the
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Table 2 Proportion (N) of outlets censused with at least one anti-malarial in stock on the day of interview, by sector, outlet type and country¹
Public Sector/Not-for-Profit Private Sector Total
Public
Health
Facility
Community
Health Worker
Private not-for-profit
Health Facility
Total
Public/Not-
for-Profit
Private
Health
Facility
Pharmacy Drug
Store
Grocery
Store
Other Outlet Types Total
Private
All
Shop/Kiosk/Bar/
Market Stall
Itinerant
Provider
Benin 95.4 (182) - 91.2 (47) 94.0 (229) 84.2 (118) 96.7 (118) - 30.5 (433) 34.4 (691) 42.7 (81) 36.3 (1, 441) 39.0 (1, 670)
DRC 96.8 (111) - 97.2 (33) 96.9 (144) 75.7 (204) 100.0 (33) 96.5 (1, 089) - 1.7 (2, 245) - 24.9 (3, 571) 28.4 (3, 715)
Madagascar 96.8 (531) 26.8 (226) 80.6 (7) 40.4 (764) 87.6 (87) 99.6 (69) 97.4 (263) 33.1 (5, 056) 1.1 (530) - 33.9 (6, 005) 35.0 (6, 769)
Nigeria 91.8 (255) 80.0 (19) 98.7 (11) 89.2 (285) 91.4 (405) 99.5 (409) 95.6 (1, 031) 3.8 (2, 141) 2.5 (1, 164) 70.2 (21) 25.7 (5, 171) 26.6 (5, 456)
Uganda 95.4 (525) 39.8 (90) 88.6 (11) 69.6 (626) 96.2 (208) 99.3 (97) 96.4 (398) 0.4 (3, 747) 0.0 (191) - 13.9 (4.641) 17.0 (5, 267)
Zambia 97.4 (165) - 100.0 (16) 97.8 (181) 92.3 (34) 100.0 (50) 76.5 (165) 3.7 (1, 946) 0.4 (997) 14.7 (5) 6.3 (3, 197) 9.5 (3, 378)
¹In Benin the drug store category was deemed redundant as, strictly, there were no unregulated private-sector medicine vendors operating from formal structures (such as permanent buildings). In Benin, such
medicine selling outlets should be registered and appear on the list of pharmacies. Unregulated vendors do operate however, often in markets, and were thus captured by the market stall and market shop
classifications. In the DRC, grocery stores, as defined for all other countries, were very rare. In the DRC and Zambia, community health workers were not targeted for inclusion due to difficulties in ascertaining their
presence in the clusters. In Benin, community health workers were not formally included in the Ministry of Health structure at the time of data collection [25]. It is expected that community health workers will be
included in later survey rounds, as their numbers increase and as the Ministry of Health makes moves to include them explicitly in national policy [26].
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DRC, where public-sector patients pay for anti-malarials,
the median prices were $1.29 (Inter Quartile Range
[IQR]: $1.29, $1.29) and $0.52 (IQR: $0.00, $1.29)
respectively for an adult equivalent treatment dose (see
Additional File 2 Table 2).
Private sector first-line quality-assured ACT prices
varied considerably between countries (Table 4). Their
median price per AETD was highest in Zambia ($9.63;
IQR: $3.01, $11.04), over $6 in Nigeria (IQR: $5.05,
$6.74), $4.50 in Uganda (IQR: $2.49, $5.97), around $3
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Figure 1 Outlets stocking anti-malarials, by outlet type.
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in Benin (IQR: $1.94, $5.77), under $2 in the DRC (IQR:
$1.03, $3.61), and lowest in Madagascar ($0.14; IQR:
$0.10, $0.57), where subsidized ACT was distributed
through a social marketing campaign.
The median private sector AETD price of the most
popular anti-malarial in tablet form, either SP or chloro-
quine in each country, ranged from $0.36 (IQR: $0.36,
$0.36) to $0.65 (IQR: $0.43, $1.08). This was
Table 3 Outlets with specific anti-malarial categories as a percentage of outlets with at least one anti-malarial in
stock, by sector¹
Benin DRC Madagascar Nigeria Uganda Zambia
Public/
Not- for-
Profit
Private Public/
Not- for-
Profit
Private Public/
Not- for-
Profit
Private Public/
Not- for-
Profit
Private Public/
Not- for-
Profit
Private Public/
Not- for-
Profit
Private
N=212 N=632 N=134 N=1,
240
N=560 N=1,
854
N=249 N=1,
864
N=534 N=691 N=176 N=259
Any ACT 71.4 a 6.4 b 84.4 a 52.7 b 92.2 a 8.4 b 60.6 a 36.7 a 81.5 a 20.1 b 82.2 a 19.3 b
First-line
quality-assured
ACT
66.4 a 5.7 b 75.8 a 24.5 b 91.9 a 7.9 b 49.2 a 25.3 b 73.4 a 7.8 b 81.5 a 16.3 b
Quality-
assured ACT
66.4 a 5.9 b 78.7 a 29.0 b 91.9 a 8.1 b 49.2 a 26.1 a 73.4 a 8.1 b 81.5 a 16.3 b
Non-Quality-
assured ACT
5.1 a 0.5 b 5.6 a 23.6 b 0.3 a 0.3 a 11.5 a 10.5 a 9.3 a 15.2 a 0.8 a 2.9 b
Any non-
artemisinin therapy
96.7 a 99.7 b 93.8 a 97.8 a 36.3 a 99.3 b 81.7 a 98.2 b 68.6 a 99.6 b 98.4 a 98.8 a
Chloroquine 9.3 a 82.1 b 0.0 a 4.0 b 1.6 a 95.5 b 57.7 a 91.9 b 15.5 a 61.0 b 0.0 a 21.7 b
SP 51.2 a 15.8 b 66.9 a 57.9 a 22.0 a 9.2 a 62.7 a 78.3 a 49.9 a 68.2 a 65.5 a 80.2 a
Quinine 92.5 a 24.0 b 85.7 a 84.3 a 23.3 a 10.7 a 20.0 a 9.2 a 59.0 a 82.9 b 89.1 a 16.8 b
Quinine
injection
60.0 a 8.0 b 65.6 a 40.7 b 20.9 a 9.5 a 19.0 a 0.6 b 56.4 a 32.6 a 51.2 a 8.7 b
Oral artemisinin
monotherapy
3.8 a 0.7 a 10.2 a 40.5 b 0.0 a < 0.1 a 4.1 a 45.1 b 1.3 a 13.3 b 1.1 a 2.5 a
¹Statistical comparisons conducted across outlet types, within countries. Statistical difference is labelled with a superscript, a or b. Proportions with different
letters in their superscripts differ significantly from one another within countries (p < 0.05 for all tests).
Table 4 Median price in US dollar (inter-quartile range) for an adult-equivalent treatment dose in the private sector
(tablet formulation only), by anti-malarial type
Median $ (IQR)
Most
Popular¹
First-line
quality-assured ACT
Oral Artemisinin Monotherapy
Benin2 0.65 a (0.43, 1.08) N = 462 3.24 b (1.94, 5.77) N = 216 8.10 (8.07, 10.45) N = 56
DRC 0.39 a (0.26, 0.52) N = 1, 258 1.86 b (1.03, 3.61) N = 252 3.23 (2.45, 4.13) N = 956
Madagascar 0.36 a (0.36, 0.36) N = 1, 847 0.14 b (0.10, 0.57) N = 302 (0 and 7.33) N = 2
Nigeria3 0.54 a (0.40, 0.81) N = 4, 061 6.40 b (5.05, 6.74) N = 372 3.24 (2.70, 3.77) N = 1, 438
Uganda4 0.50 a (0.30, 0.75) N = 653 4.48 b (2.49, 5.97) N = 81 9.55 (7.96, 11.94) N = 229
Zambia 0.40 a (0.30, 0.61) N = 261 9.63 b (3.01, 11.04) N = 83 6.74 (5.72, 6.74) N = 16
¹ The most popular ACT was chloroquine in Madagascar, and SP in all other countries. The most popular anti-malarial is based on volumes of anti-malarials sold
or distributed in the last week, within each country.
2 Statistical comparisons were conducted between the most popular treatment and the first-line quality-assured ACT. Statistical difference is labelled with
superscripts ‘a’ or ‘b’. Estimates with different letters in their superscripts differ significantly from one another within countries (p < 0.01 for all tests).
3 In Nigeria, price is presented for the first-line quality-assured ACT (AL), rather than the alternate first-line quality-assured ACT (ASAQ). The median price for the
alternate first-line treatment in Nigeria is $3.23 (1.89, 4.04) N = 622.
4 In Uganda the sampled clusters included two areas located in districts that were undertaking a pilot of subsidized ACT in the retail sector [27]. Due to the
presence of this pilot, the percent of private sector outlets stocking ACT was somewhat greater in these clusters than in the rest of the sample (50% and 19%
respectively). These areas comprised 1.4% of the total sample of private outlets, and while accounting for only 5.4% of the private sector ACT products audited
(25 out of 459 ACTs) they accounted for 17% of ACT products once sampling weights are taken into account (these clusters have high weights because they had
a relatively low chance of selection under PPS). As in the pilot districts private sector ACT had a much lower price than elsewhere in the country, inclusion of the
two pilot clusters can give a distorted picture of the average price available across the country as a whole. Uganda findings are therefore calculated both with
and without the subsidized product observations from the 2 clusters for the first-line quality assured treatment. Data in the price table are presented excluding
the subsidized product piloted in the clusters. The inclusion of the subsidized products provides a lower price for the first line quality assured treatment of $0.38
(0.38, 4.73) N = 104.
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significantly lower (p < 0.01) than the median price of
the first-line quality-assured ACT in each country, with
Madagascar as an exception, where the first-line quality-
assured ACT was significantly less expensive than the
most popular anti-malarial, chloroquine.
Overall, the median price of chloroquine tablets ran-
ged from $0.24 (IQR: $0.24, $0.48) to $0.48 (IQR: $0.48,
$0.48) and SP from $0.38 (IQR: $0.29, $ 0.48) to $0.65
(IQR: $0.43, $1.08) in the private sector (see Additional
File 3 Table 3).
Median prices of oral artemisinin monotherapies in
the private sector ranged from $3.23 in the DRC (IQR:
$2.45, $4.13) to $9.55 in Uganda (IQR: $7.96, $11.94).
Market share
Figure 2 shows the market share of different categories of
anti-malarials sold or distributed in the seven days prior to
the survey. With the exception of Zambia, the private sec-
tor played a larger role than the public/not-for-profit sec-
tor in the distribution of anti-malarials. This difference
was most pronounced in Nigeria, where 98% of anti-
malarial volumes were delivered through the private sector
and only 2% of these were quality-assured ACT.
For most countries, non-artemisinin therapies domi-
nated the overall market, followed by ACT and then
oral artemisinin monotherapies. Exceptions to this find-
ing were noted in Nigeria and the DRC where more
oral artemisinin monotherapies were sold than ACT in
the private sector. Across all countries quality-assured
ACT accounted for less than 25% of total anti-malarial
volumes; private-sector quality-assured ACT volumes
represented less than 6% of the total market share. In
the public/not-for-profit sector, SP made up the largest
market share of non-artemisinin therapies (Benin,
11.6%; the DRC, 16.2%; Madagascar, 9.5%; Nigeria 1.4%;
Uganda, 21.6%; Zambia, 34.1%).
Provider knowledge
Knowledge of the first-line treatment was significantly
higher in the public/not-for-profit sector than the
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Figure 2 Relative volumes of anti-malarials sold/distributed in the last seven days, by public/not-for-profit and private sectors and
anti-malarial category¹. ¹For each country, the public/not for profit and private columns sum to 100%. The figure shows 1) the contribution of
the pubic/not for profit and private market share of each sector and 2) the breakdown of each sector’s sales by antimalarial type.
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private sector across all countries: 44% to 93% of provi-
ders in the public/not-for-profit sector could correctly
state the first-line treatment, compared with 12% to 60%
in the private sector (Table 5). Similar patterns were
found for provider knowledge of the dosing regimens
for the first-line treatment in children and adults.
Knowledge of any dosing regimens was particularly low
for the private sector in Benin and Madagascar, where
less than 10% of providers were able to describe any
child or adult regimen correctly.
Diagnostics
Each outlet was assessed for the availability of rapid
diagnostic tests (RDTs) (see Additional File 4 Table 4).
In the public/not-for-profit sector, availability varied
considerably by country (Benin, 72%; the DRC, 36%;
Madagascar, 43%; Nigeria, 7%; Uganda, 22% and Zam-
bia, 86%). In the private sector, availability was less than
20% and significantly lower across all countries than in
the public/not-for-profit sector.
Discussion
This paper presents standardized, nationally representa-
tive data on the anti-malarial market in six sub-Saharan
African countries between 2009 and 2010. The data
confirm the low market share of ACT, reflecting a com-
bination of low ACT availability in both the public/not-
for-profit and private sectors, high ACT prices in the
private sector and low provider ACT knowledge, parti-
cularly in the private sector. Other studies have high-
lighted similar challenges [8,10,11,17,28]. The following
sub-sections describe the limitations of the ACTwatch
outlet surveys, summarize the main findings according
to availability, price, market share and provider
knowledge, and address the policy implications of these
results.
Strengths and limitations
The ACTwatch survey methodology allows for the mea-
surement of anti-malarial availability and prices in a
standardized way, on a nationally representative sample
of outlets, with multiple steps to ensure data quality.
When combined with the ACTwatch household survey
[29], and the supply chain study on the structure and
operation of the anti-malarial distribution chain, ACT-
watch data provide a full picture of the anti-malarial
market, with multiple uses for policy making.
Despite the study’s strengths, the outlet survey data
presented here have several limitations. 1) Providers
may have had incentives to mis-report certain informa-
tion, such as whether they stocked any anti-malarials, or
specific anti-malarial categories, especially if this was
not permitted by government regulations. Although
interviewers stressed that they were not connected with
any regulatory body, anti-malarial availability and stocks
may have been under-reported. 2) Volumes were based
purely on provider recall. Given the lack of sales records
in most private outlets, this was felt to be the most
logistically feasible method for estimating volumes, but
it is likely that some recall bias was present. 3) Adult
equivalent treatment dose calculations were used when
calculating prices and volumes. This has the advantage
of allowing direct comparability between drugs. How-
ever, it should be noted that in practice many customers
will be obtaining drugs for children and/or purchasing
incomplete doses [30]. As a result, the price actually
paid per customer may be considerably lower than the
median price per AETD. Similarly, the actual number of
Table 5 Provider knowledge of first-line treatment and dosing regimens, by sector¹
Benin DRC Madagascar Nigeria Uganda Zambia
Public/
Not-for-
Profit
Private Public/
Not-
for-
Profit
Private Public/
Not-
for-
Profit
Private Public/
Not-
for-
Profit
Private Public/
Not-
for-
Profit
Private Public/
Not-
for-
Profit
Private
N=218 N=735 N=135 N=1,
242
N=575 N=2,
016
N=258 N=1,
839
N=563 N=699 N=178 N=283
Correctly state the
recommended first-line
treatment for uncomplicated
malaria
73.0 a 17.7 b 76.4 a 42.4 b 71.7 a 12.4 b 43.7 a 25.5 b 92.8 a 59.8 b 92.7 a 59.3 b
Correctly state the dosing
regimen of the first-line
treatment for an adult
70.7 a 8.4 b 70.4 a 28.5 b 42.4 a 5.1 a –2 – 86.6 a 53.2 a 92.7 a 48.2 b
Correctly state the dosing
regimen of the first-line
treatment for a two year old
70.2 a 7.8 b 69.6 a 28.4 b 68.8 a 8.5 b – – 89.5 a 49.3 b 92.7 a 47.3 b
¹ Statistical comparisons conducted across outlet types, within countries. Statistical difference is labelled with a superscript, a or b. Proportions with different
letters in their superscripts differ significantly from one another within countries (p < 0.01 for all tests).
2 Information on Nigeria’s dosing regimen for their first-line alternative ACT, ASAQ, was not collected.
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customers to whom each drug was sold will be consid-
erably higher than the volume of AETDs dispensed. It
should also be noted that AETD prices presented in this
paper do not include additional fees that may have been
incurred for customers, such as consultation fees or ser-
vice charges. 4) While price indicators were standar-
dized according to the 2009 US dollar, it is
acknowledged that there are different costs of living
within countries and varying average or minimum
wages, which make like-with-like comparisons across
countries challenging. 5) Data were only collected at
one point in the year, generally around the peak malaria
transmission season. Seasonal variation may be
expected, meaning in particular that anti-malarial avail-
ability and sales volumes may have been higher during
the surveys than their annual averages, especially in
countries with marked seasonal transmission, such as
Madagascar and Zambia. 6) While a methodological
strength of the survey is the full census of outlets in
selected clusters, there are a number of practical imple-
mentation challenges with this method. Conducting a
full census requires interviewers in the clusters to screen
every outlet. It is acknowledged that some outlets with
the potential to sell anti-malarials may have been
missed, thus distorting the true figure of anti-malarial
availability across countries.
Availability
Overall availability of ACT was low, particularly in the
private sector. In the private sector, non-artemisinin
therapies, typically chloroquine or SP, were by far the
most abundant anti-malarial available while first-line
quality-assured ACT was available in less than one-
quarter of the anti-malarial stocking outlets. Oral arte-
misinin monotherapies were available in more than 40%
of private sector anti-malarial-stocking outlets in the
DRC and Nigeria. Within the public/not-for-profit sec-
tor, quality-assured ACT stockage rates ranged between
49%-92%.
When observing stocking rates for all public health
facilities, availability of ACT hovered around 80%, but in
Nigeria less than half of facilities had a quality assured
ACT in stock. This suggests that maintaining a consis-
tent supply to public health facilities may be difficult, a
finding supported by other facility based research, which
also highlights stock-outs as a common problem in pub-
lic health facilities [31].
Price
With one notable exception in Madagascar, first-line
quality-assured ACT treatment in the private sector was
significantly more expensive, between 5-23 times so,
than the most popular anti-malarial (chloroquine or SP).
Given the importance of the private sector in
distributing anti-malarials, the higher cost of first-line
quality-assured ACT is a concern. Although ACT is free
or at a low price in the public sector, this is not where
the majority of people seek treatment [29].
In Madagascar, the price of quality-assured ACT in
the private sector is exceptionally low at $0.14. This is
due to the presence of a socially-marketed ACT, which
is sold nationally at a highly subsidized price through
pharmacies and drug stores. This mirrors findings from
a pilot subsidy programme in Tanzania which demon-
strated that after the introduction of an ACT subsidy,
ACT prices were as low as $0.58 in the private sector
and did not differ significantly from the price paid for
SP, the most common alternative [32].
Market share
Market share data highlight the dominant role of the
private sector across all countries except Zambia, where
60% of all anti-malarials pass through the public/not-
for-profit sector. Of the other countries, the private sec-
tor was the most important in Nigeria accounting for
98% of anti-malarial sales volumes, and elsewhere ran-
ged from 58%-82%. Unfortunately, most of the anti-
malarials sold through the private sector are non- arte-
misinin therapies, as well as concerning amounts of oral
artemisinin monotherapies in the DRC and Nigeria (7%-
8% of the total market). ACT comprised less than 25%
of the total volume of anti-malarials distributed across
all sectors. Quality-assured ACT fared even worse in the
private sector, where it generally accounted for less than
6% of the total market share.
Of note, in Nigeria and the DRC, the market share of
ACT was particularly low and more oral artemisinin
monotherapies were sold than ACT in the private sec-
tor. In Nigeria, oral artemisinin monotherapy is less
expensive than first-line quality-assured ACT treatment,
perhaps explaining why higher volumes of oral artemisi-
nin monotherapies are found.
Provider knowledge
Provider knowledge was generally lower in the private
sector than in the public/not- for-profit sector. Other
studies have shown that medicine seller knowledge of
drugs and doses, particularly in the private sector, is
often poor [13,15,16]. This is likely to be exacerbated by
the relatively recent introduction of ACT in sub-Saharan
Africa because these have new dosage requirements and
more than one product may be available with different
dosages [13].
Policy implications
Poor ACT availability in both public/not-for-profit and
private sectors, as well as the high price observed in the
private sector, and poor provider knowledge, serve as
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barriers to obtaining effective treatment. Of grave con-
cern, quality-assured ACT availability in the public sec-
tor ranges between 43-85%. This suggests that there are
issues within the public-sector supply chain that require
urgent attention, especially in Nigeria and Uganda
where stocking rates were lowest.
In the private sector, non-artemisinin therapies are
more widely available and more commonly sold than
other classes of anti-malarials; these medicines are also
usually sold at a much lower price than ACT. Given the
relative affordability and accessibility of non-artemisinin
therapies, consumers have strong incentives to choose
the ‘wrong’, ineffective, anti-malarial when seeking
treatment.
Oral artemisinin monotherapy, discouraged for its
potential to speed the spread of artemisinin resistance,
was commonly available and sold at private outlets in
the DRC and Nigeria. These disappointing findings
should act as a rallying call given the Millennium Devel-
opment Goal targets and that together these two nations
account for nearly half of the total global burden of
malaria disease [33]. While all the ACTwatch countries
have taken regulatory measures to withdraw the market-
ing authorization of oral artemisinin monotherapies, the
manufacturing and marketing of these products is still
ongoing (and many of these companies are located in
Nigeria, though renewal licenses will not be granted to
existing companies currently marketing oral artemisinin
monotherapies [34]). This calls into question the effec-
tiveness of current regulatory practices in countries
where this drug is banned. Interventions such as tighter
regulation and building awareness of issues with oral
artemisinin monotherapies should be considered so that
this national policy of public health significance is
indeed followed. For other countries, availability of oral
artemisinin monotherapy was low, suggesting a positive
outcome from the 2006 WHO regulatory ban on oral
artemisinin monotherapy, and heightened government
response to the threat of artemisinin resistence.
As the majority of anti-malarials are delivered through
the private sector, there is a clear need to consider how
to handle the role of the private sector when developing
anti-malarial drug policies. Some argue that emphasis
should remain on the public sector, to attract more peo-
ple to outlets where care is regulated and provided by
qualified staff [35]. Others argue that, given the current
state of developing country health systems, while the
public sector cannot be ignored, high private sector use
is inevitable in many countries, and therefore strategies
should be adopted to improve its quality [36]. The
extent to which the emphasis should be placed on the
private sector continues to be debated [37] and data
presented here provide evidence to help facilitate further
discussion.
Prominent among private sector initiatives is the
Affordable Medicines Facility for Malaria (AMFm),
which began operations in pilot countries during 2010,
and provides a mechanism for heavily subsidized, qual-
ity-assured ACT to be sold at a target retail price of
$0.50 [21]. However, there continues to be controversy
about such initiatives, with some arguing that the sub-
sidy will be captured by middle-men in the distribution
chain; that market power in the private sector will lead
to continued problems of affordability and inaccessibility
by the poor; and that widespread availability of ACT
without improving access to diagnosis will result in mis-
use of ACT and fuel the development of resistance
[35,38].
Of the countries covered in this paper, Madagascar
provides an interesting example of a setting where an
ACT subsidy has been in operation since 2008. The sub-
sidized ACT was open to all wholesalers registered or
unregistered in the country and it was sold nationally
through community health workers, pharmacies and
rural drug stores. The ACT did not have over-the-coun-
ter status and had a recommended retail price of $0.05.
In contrast to the other countries, the price of quality-
assured ACT was lower than non-artemisinin therapies.
However, accessibility remained low, as ACTwatch data
show that less than 10% of private sector outlets stock-
ing this type of ACT. Provider knowledge of the first-
line treatment was also low (12%). As such, substantial
gains in market share of ACT were not apparent, and
rates of ACT use in febrile children remained less than
5% [29]. Despite this, smaller scale pilots of ACT subsi-
dies have shown impressive results [27,32,39]. Promising
findings have also been demonstrated in Cambodia,
where an ACT social marketing programme has been in
place for the past 10 years [40].
The data suggest a need for interventions to address a
full range of supply side issues that go above and
beyond a price subsidy (i.e. targeting provider knowl-
edge, increasing supply and product promotion). Inter-
ventions should also focus on demand creation through
activities that include behaviour change communication,
to encourage the stocking and uptake of ACT, particu-
larly in the private sector. It remains to be seen how far
the “supporting interventions, “ (e.g. provider trainings
and behaviour change communication, all to promote
ACT utilization), being implemented as part of the
AMFm and other initiatives will go in addressing these
concerns.
Conclusions
ACTwatch provides standardized, nationally representa-
tive data on anti-malarial supply from multiple countries
collected within 16 months. Data presented in this paper
report on key, policy relevant indicators across
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countries. The results typically demonstrate the low
availability, low market share and high price of ACT, at
least in the private sector where most anti-malarials are
being accessed, with some exceptions. Data from ACT-
watch outlet surveys confirm that there is substantial
room to improve availability and affordability of ACT
treatment in six countries across sub-Saharan Africa,
and in both the public/not-for-profit and private sectors.
The data will also be useful for monitoring the impact
of interventions such as the Affordable Medicines Facil-
ity for malaria. More detailed, country specific findings
(for example, outlet anti-malarial availability by country
strata) can be found in country reports on the ACT-
watch website [41].
Additional material
Additional file 1: Proportion of all public health facilities stocking at
least one anti-malarial on the day of survey. This table shows the
availability of different categories of anti-malarials in public health
facilities as the proportion of facilities with anti-malarials in stock, among
all censused public health facilities.
Additional file 2: Median price in US dollar (inter-quartile range) of
adult-equivalent anti-malarial treatment doses in the public sector
(tablet formulation). This table shows the median price of the first-line
quality assured ACT anti-malarial treatment doses in the public sector
across all countries.
Additional file 3: Median price in US dollar (inter-quartile range) of
adult-equivalent anti-malarial treatment doses in the private sector
(tablet formulation), by antimalarial type. this table shows the
median price of SP and CQ anti-malarial treatment doses in the private
sector across all countries.
Additional file 4: Percent of outlets stocking RDTs, by outlet
category. This table shows the availability of RDTs in public/not for
profit and private sectors across all countries.
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